Drugs & Therapy Perspectives

, Volume 11, Issue 6, pp 5–8 | Cite as

Aggressive non-Hodgkin’s lymphoma: improved prognosis with combination chemotherapy

New Drugs and Disease Management


Bleomycin Fenofibrate Fluvastatin International Prognostic Index Calcium Folinate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Martelli M, De Sanctis V, Avvisati G, et al. Current guidelines for the management of aggressive non-Hodgkin’s lymphoma. Drugs 1997 Jun; 53(6): 957–72PubMedCrossRefGoogle Scholar
  2. 2.
    Weisenburger DD. Epidemiology of non-Hodgkin’s lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 1994; 5(9): 19–24PubMedGoogle Scholar
  3. 3.
    Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive NHL: the international non-Hodgkins lymphoma factors project. N Engl J Med 1993; 329: 987–94CrossRefGoogle Scholar
  4. 4.
    Gordon LI, Harringhton D, Andersen PDJ, et al. Comparison of a second-generation combination chemotherapy regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkins NHL. N Engl J Med 1992; 327: 1342–9PubMedCrossRefGoogle Scholar
  5. 5.
    Montserrat E, Garcia-Conde J, Vinolas N, et al. ProMACE-CytaBOM vs CHOP in the treatment of unfavorable lymphomas: a randomized trial [abstract]. Blood 1991; 78: 127AGoogle Scholar
  6. 6.
    Cooper IA, Wolf MM, Robertson TI, et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin’s lymphoma. J Clin Oncol 1994; 12: 769–78PubMedGoogle Scholar
  7. 7.
    Fisher RI. CHOP is the current standard for the treatment of high risk patients with diffuse large cell lymphoma [abstract no. 036]. VIth International Conference on Malignant Lymphoma; 1996 Jun 5–8: Lugano. Ann Oncol 1996; 7 Suppl. 3: 12Google Scholar
  8. 8.
    Bertini M, Orsucci L, Vitolo U, et al. Stage II large B-cell lymphoma with sclerosis treated with MACOP-B. Ann Oncol 1991; 2: 733–7PubMedGoogle Scholar
  9. 9.
    Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993; 11(12): 2306–13PubMedGoogle Scholar
  10. 10.
    Falini B, Venturi S, Martelli M, et al. Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. Br J Haematol 1995; 89: 780–9PubMedCrossRefGoogle Scholar
  11. 11.
    Haioun C, Gaulard P, Roudot-Thovaral F, et al. Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol 1989; 12: 425–9PubMedCrossRefGoogle Scholar
  12. 12.
    Todeschini G, Ambrosetti A, Meneghini V, et al. Mediastinal large B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol 1990; 8: 804–8PubMedGoogle Scholar
  13. 13.
    Lavabre-Bertrand T, Donadio D, Feguex N, et al. A study of 15 cases of primary mediastinal lymphoma of B-cell type. Cancer 1992; 69: 2561–6PubMedCrossRefGoogle Scholar
  14. 14.
    Longo DL, Glatstein E, Duffey PL, et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 1989; 9: 1295–302Google Scholar
  15. 15.
    Tondini C, Zanini M, Lombardi F, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin’s lymphomas. J Clin Oncol 1993; 4: 720–5Google Scholar
  16. 16.
    Connors JM, Klimo P, Fairey RN, et al. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 1987; 107: 25–30PubMedGoogle Scholar
  17. 17.
    Miller TP, Dahlberg S, Cassady JR, et al. Three cycles of CHOP (3) plus radiotherapy (RT) is superior to eight cycles of CHOP (8) alone for localized intermediate and high grade non-Hodgkins lymphoma: a Southwest Oncology Study Group [abstract no. 1257]. Proceedings of the XXXIIth ASCO Meeting; 1996 May 18–21: PhiladelphiaGoogle Scholar

Copyright information

© Adis International Limited 1998

Personalised recommendations